Danske Bank’s Fortress Biotech FBIO Stock Holding History

Danske Bank’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3	Closed	-$4	–	1485
2024 Q3	$4	Buy	+3	New	+$6	﹤0.01%	1555

Other funds holding FBIO

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Danske Bank's FBIO Position: Q4 2024 in Review

Danske Bank sold out of Fortress Biotech (FBIO) in Q4 2024, closing a stake of 3 shares — an estimated $4 sold.

Danske Bank first reported a position in FBIO in Q3 2024 and held it in 1 quarter. The position peaked at $4 in Q3 2024. 53 funds tracked by Wall St. Rank hold FBIO as of Q4 2024.

Danske Bank reported no remaining Fortress Biotech position as of Q4 2024 after selling out during the quarter.
Danske Bank sold 3 Fortress Biotech shares in Q4 2024, an estimated $4.
Danske Bank first reported a position in Fortress Biotech in Q3 2024 and held it in 1 quarter.
Danske Bank's Fortress Biotech position peaked at $4 in Q3 2024.
53 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2024.

Based on Danske Bank's 13F filing for Q4 2024, filed 18 Mar 2026.